Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis

•We used the NCDB to analyze consolidative thoracic radiation in extensive stage SCLC.•A dose of at least 45 Gy compared to less than 45 Gy was an independent predictor of survival.•In select extensive stage SCLC patients dose escalated thoracic radiotherapy may be considered. Randomized studies hav...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2018-10, Vol.124, p.283-290
Main Authors: Hasan, Shaakir, Renz, Paul, Turrisi, Andrew, Colonias, Athanasios, Finley, Gene, Wegner, Rodney E.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinoma, Small Cell - diagnosis
Carcinoma, Small Cell - mortality
Carcinoma, Small Cell - radiotherapy
Databases, Factual
Dose escalation
Extensive stage
Female
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - mortality
Lung Neoplasms - radiotherapy
Male
Middle Aged
National Cancer Database
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Propensity Score
Radiotherapy Dosage
SCLC
Small cell lung cancer
Survival Analysis
Thoracic radiotherapy
Thorax - radiation effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We used the NCDB to analyze consolidative thoracic radiation in extensive stage SCLC.•A dose of at least 45 Gy compared to less than 45 Gy was an independent predictor of survival.•In select extensive stage SCLC patients dose escalated thoracic radiotherapy may be considered. Randomized studies have demonstrated a survival benefit for consolidative thoracic radiotherapy (TRT) in extensive stage (ES) small cell lung cancer (SCLC), however the radiation dose and optimal selection criteria are often debated. We analyzed 3280 stage IV SCLC treated with double-agent chemotherapy and TRT within the National Cancer Data Base (NCDB) and evaluated the differences in selection patterns and survival outcomes for patients who received at least 45 Gy of TRT and those who received
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2018.08.016